FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2936696080> ?p ?o ?g. }

• W2936696080 endingPage "655" @default.
• W2936696080 startingPage "646" @default.
• W2936696080 abstract "Gastrin‐releasing peptide receptors (GRPRs) are overexpressed in prostate cancer, representing attractive targets for diagnosis and therapy with bombesin (BBN)‐like radioligands. GRPR‐antagonists have lately attracted much attention owing to inherent biosafety and favorable pharmacokinetics. We herein present the GRPR‐antagonist SB9 structurally resembling the known BBN‐based agonist AMBA (SB9 = [Leu 13 NHEt‐ des Met 14 ]AMBA). The profiles of 111 In‐SB9 and 111 In‐AMBA were directly compared in PC‐3 cells and tumor‐bearing mice. SB9 and AMBA displayed high GRPR affinities. 111 In‐AMBA strongly internalized in PC‐3 cells, while 111 In‐SB9 remained bound on the cell surface showing a typical GRPR‐radioantagonist profile. 111 In‐SB9 was more stable than 111 In‐AMBA, but coinjection of the neprilysin (NEP) inhibitor phosphoramidon (PA) stabilized both in vivo. The radioligands displayed high tumor uptake (20.23 ± 3.41 %ID/g and 18.53 ± 1.54 %ID/g, respectively, at 4 hours pi), but 111 In‐SB9 washed faster from background. PA coinjection led to significant increase of tumor uptake, combined with better clearance for 111 In‐SB9. In short, this study has revealed superior pharmacokinetics and higher stability for the GRPR‐antagonist 111 In‐SB9 vs the corresponding agonist 111 In‐AMBA consolidating previous evidence that GRPR antagonists are preferable to agonists for tumor imaging and therapy. It has also demonstrated that further pharmacokinetic improvements were feasible by in situ metabolic radioligand stabilization using PA." @default.
• W2936696080 created "2019-04-25" @default.
• W2936696080 creator A5007991478 @default.
• W2936696080 creator A5018579790 @default.
• W2936696080 creator A5028193938 @default.
• W2936696080 creator A5029897786 @default.
• W2936696080 creator A5040369608 @default.
• W2936696080 creator A5041965340 @default.
• W2936696080 creator A5079838266 @default.
• W2936696080 date "2019-06-13" @default.
• W2936696080 modified "2023-10-16" @default.
• W2936696080 title "Comparative evaluation of the new GRPR-antagonist ¹¹¹ In-SB9 and ¹¹¹ In-AMBA in prostate cancer models: Implications of in vivo stability" @default.
• W2936696080 cites W1554560710 @default.
• W2936696080 cites W1966952526 @default.
• W2936696080 cites W1975602223 @default.
• W2936696080 cites W1983792141 @default.
• W2936696080 cites W1989743694 @default.
• W2936696080 cites W2000181720 @default.
• W2936696080 cites W2000200102 @default.
• W2936696080 cites W2001213717 @default.
• W2936696080 cites W2009693156 @default.
• W2936696080 cites W2060564910 @default.
• W2936696080 cites W2062489834 @default.
• W2936696080 cites W2095531714 @default.
• W2936696080 cites W2101301092 @default.
• W2936696080 cites W2116326600 @default.
• W2936696080 cites W2123941740 @default.
• W2936696080 cites W2131970757 @default.
• W2936696080 cites W2144240397 @default.
• W2936696080 cites W2183255199 @default.
• W2936696080 cites W2301515918 @default.
• W2936696080 cites W2504946646 @default.
• W2936696080 cites W2584096092 @default.
• W2936696080 cites W2605247297 @default.
• W2936696080 cites W2621533279 @default.
• W2936696080 cites W2777856431 @default.
• W2936696080 cites W2793800261 @default.
• W2936696080 cites W2799952457 @default.
• W2936696080 doi "https://doi.org/10.1002/jlcr.3733" @default.
• W2936696080 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30963606" @default.
• W2936696080 hasPublicationYear "2019" @default.
• W2936696080 type Work @default.
• W2936696080 sameAs 2936696080 @default.
• W2936696080 citedByCount "7" @default.
• W2936696080 countsByYear W29366960802019 @default.
• W2936696080 countsByYear W29366960802020 @default.
• W2936696080 countsByYear W29366960802021 @default.
• W2936696080 countsByYear W29366960802022 @default.
• W2936696080 crossrefType "journal-article" @default.
• W2936696080 hasAuthorship W2936696080A5007991478 @default.
• W2936696080 hasAuthorship W2936696080A5018579790 @default.
• W2936696080 hasAuthorship W2936696080A5028193938 @default.
• W2936696080 hasAuthorship W2936696080A5029897786 @default.
• W2936696080 hasAuthorship W2936696080A5040369608 @default.
• W2936696080 hasAuthorship W2936696080A5041965340 @default.
• W2936696080 hasAuthorship W2936696080A5079838266 @default.
• W2936696080 hasConcept C104826730 @default.
• W2936696080 hasConcept C112705442 @default.
• W2936696080 hasConcept C118303440 @default.
• W2936696080 hasConcept C121608353 @default.
• W2936696080 hasConcept C126322002 @default.
• W2936696080 hasConcept C150903083 @default.
• W2936696080 hasConcept C170493617 @default.
• W2936696080 hasConcept C181199279 @default.
• W2936696080 hasConcept C185592680 @default.
• W2936696080 hasConcept C20417620 @default.
• W2936696080 hasConcept C207001950 @default.
• W2936696080 hasConcept C2776885963 @default.
• W2936696080 hasConcept C2778448772 @default.
• W2936696080 hasConcept C2778938600 @default.
• W2936696080 hasConcept C2780192828 @default.
• W2936696080 hasConcept C502942594 @default.
• W2936696080 hasConcept C55493867 @default.
• W2936696080 hasConcept C67847695 @default.
• W2936696080 hasConcept C71924100 @default.
• W2936696080 hasConcept C86803240 @default.
• W2936696080 hasConcept C98274493 @default.
• W2936696080 hasConceptScore W2936696080C104826730 @default.
• W2936696080 hasConceptScore W2936696080C112705442 @default.
• W2936696080 hasConceptScore W2936696080C118303440 @default.
• W2936696080 hasConceptScore W2936696080C121608353 @default.
• W2936696080 hasConceptScore W2936696080C126322002 @default.
• W2936696080 hasConceptScore W2936696080C150903083 @default.
• W2936696080 hasConceptScore W2936696080C170493617 @default.
• W2936696080 hasConceptScore W2936696080C181199279 @default.
• W2936696080 hasConceptScore W2936696080C185592680 @default.
• W2936696080 hasConceptScore W2936696080C20417620 @default.
• W2936696080 hasConceptScore W2936696080C207001950 @default.
• W2936696080 hasConceptScore W2936696080C2776885963 @default.
• W2936696080 hasConceptScore W2936696080C2778448772 @default.
• W2936696080 hasConceptScore W2936696080C2778938600 @default.
• W2936696080 hasConceptScore W2936696080C2780192828 @default.
• W2936696080 hasConceptScore W2936696080C502942594 @default.
• W2936696080 hasConceptScore W2936696080C55493867 @default.
• W2936696080 hasConceptScore W2936696080C67847695 @default.
• W2936696080 hasConceptScore W2936696080C71924100 @default.
• W2936696080 hasConceptScore W2936696080C86803240 @default.
• W2936696080 hasConceptScore W2936696080C98274493 @default.

• next